文献速递肿瘤 PET/CT

定量Deauville评分从18F-FDG PET应答评估中揭示预后信息:EuroNet-PHL-C1试验数据

Quantitative Deauville Scoring to Uncover Prognostic Information from 18F-FDG PET-Based Response Assessment: Data from the EuroNet-PHL-C1 Trial.
PubMed 文献 · J Nucl Med · 2025-09-02

该研究基于EuroNet-PHL-C1试验中1447例新诊断儿童经典霍奇金淋巴瘤患者,在2周期化疗后行18F-FDG PET早期应答评估,回顾性测量qPET(淋巴瘤残留SUVpeak与肝脏SUVmean的比值)。qPET与60个月无事件生存(EFS)连续相关,可将vDS5类进一步区分为预后迥异的5A与5B亚组。

要点

  • qPET<1.3时EFS约89%,对应完全代谢缓解的现行阈值(vDS≤3)。
  • vDS4且1.3<qPET≤2者EFS为84.3%,vDS5且2<qPET≤3者EFS为83.1%。
  • vDS5且qPET>3者EFS仅47.6%,属高危亚组,vDS5预后跨度达47.6%-83.1%。

核心结论

  • qPET可延伸序数性vDS并在其全范围内连续区分预后。
  • vDS5组(qPET>2.0)预后跨度宽,EFS为47.6%-83.1%。
  • qPET>3的高qPET值患者,额外信息可能为新的治疗策略提供依据。
  • qPET在1.3至3之间者,标准化疗联合放疗已足够。
  • qPET低于1.3时省略放疗,可确认良好结局。

研究设计与样本

  • 方法学论文,基于多中心EuroNet-PHL-C1试验。
  • 共纳入1447例新诊断各期儿童霍奇金淋巴瘤患者。
  • 患者接受2周期长春新碱、依托泊苷、泼尼松和多柔比星后行18F-FDG PET早期应答评估。
  • 回顾性测量对应最高vDS病灶的qPET值(淋巴瘤残留SUVpeak与肝脏SUVmean的比值)。
  • 采用逻辑回归将qPET作为60个月无事件生存(EFS)的连续生物标志物。

主要发现

  • qPET值<1.3时EFS约89%,对应完全代谢缓解的现行阈值(vDS≤3)。
  • vDS4且1.3<qPET≤2者EFS为84.3%。
  • vDS5且2<qPET≤3者EFS为83.1%。
  • vDS5且qPET>3者EFS为47.6%,属不可接受低EFS的高危小群体。
  • 定量指标使vDS5类可拆分为5A与5B,EFS率完全不同,vDS5组(qPET>2.0)EFS范围为47.6%-83.1%。

关键数值与推荐

  • qPET<1.3对应vDS≤3,EFS约89%。
  • 1.3<qPET≤2对应vDS4,EFS为84.3%。
  • 2<qPET≤3对应vDS5,EFS为83.1%。
  • qPET>3对应vDS5,EFS为47.6%。
  • vDS5组定义为qPET>2.0,EFS范围为47.6%-83.1%。

临床怎么用

  • 作者认为qPET>3的高qPET值患者,额外信息可能为新的治疗策略提供依据。
  • 作者认为qPET在1.3至3之间者,标准化疗联合放疗已足够。
  • 作者认为qPET低于1.3时省略放疗可确认良好结局。

局限性

  • qPET为回顾性测量。
  • 原文结论提出额外信息可能为高qPET值患者的新治疗策略提供依据,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cure rates are excellent in classical Hodgkin lymphoma. The challenge is tailoring the treatment to the individual patient to avoid not only overtreatment and treatment-related sequelae but also undertreatment. 18F-FDG PET is a major tool for guiding response-adapted treatment. Metabolic response is by default assessed using the visual 5-point Deauville scale (vDS), which is, however, limited by its ordinal nature. In this methodologic paper, we investigate whether a quantitative extension of the vDS, namely qPET, allows for better prognostic discrimination. Methods: In total, 1,447 patients with newly diagnosed pediatric Hodgkin lymphoma of all stages from the multicentric EuroNet-PHL-C1 trial received 2 vincristine, etoposide, prednisone, and doxorubicin cycles before they underwent 18F-FDG PET for early response assessment. The qPET value (quotient of SUVpeak of the lymphoma residual and SUVmean of the liver) corresponding to the lesion with the highest determined vDS was retrospectively measured. Logistic regression used qPET as a continuous biomarker for 60 mo of event-free survival (EFS). Results: The individual qPET value strongly relates to the EFS: EFS is high at about 89% for qPET values of less than 1.3, corresponding to the currently applied threshold for complete metabolic remission (vDS, ≤3). Among patients with a vDS of 4 or 5, qPET further discriminates a larger group with still high EFS, that is, 84.3% (1.3 < qPET ≤ 2; refers to vDS4) and 83.1% (2 < qPET ≤ 3; refers to vDS5), from a smaller, high-risk group with unacceptably low EFS at 47.6% (qPET > 3; refers to vDS5). Thus, using metric measures enabled splitting up the vDS5 category into 5A and 5B, showing totally different EFS rates. Conclusion: qPET extends the ordinal vDS and discriminates prognosis continuously over its whole range. The group of vDS5 patients (qPET > 2.0) has a particularly wide prognostic range (EFS, 47.6%-83.1%). Additional information provided by qPET may justify new treatment strategies for patients with high qPET values greater than 3, reveal that standard treatment (chemotherapy plus radiotherapy) is sufficient for patients with qPET values between 1.3 and 3, and confirm favorable outcome when radiotherapy is omitted if qPET is below 1.3.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kurch L, Landman-Parker J, Georgi TW, et al. Quantitative Deauville Scoring to Uncover Prognostic Information from 18F-FDG PET-Based Response Assessment: Data from the EuroNet-PHL-C1 Trial. J Nucl Med. 2025. PMID: 40639904. doi:10.2967/jnumed.125.269603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。